FIELD: biotechnology.
SUBSTANCE: antitumor agent is presented containing a peptide having 4 linked epitopes containing 4 CTL epitope peptides linked through linkers, and a PD-1 pathway antagonist as active ingredients. Options for using the said agent for the treatment of an oncological patient are also proposed. A method of evaluating the antitumor activity of a peptide having 4 linked epitopes and a PD-1 pathway antagonist using a cell into which a polynucleotide encoding an epitope peptide of a human tumor antigen derived from SART2 and a polynucleotide encodingα 1 andα 2 regions of human HLA-A24 are disclosed.
EFFECT: invention provides a new cancer treatment method that exhibits excellent antitumor activity and causes fewer adverse reactions.
40 cl, 9 dwg, 7 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW PEPTIDE WITH 4 LINKED CTL-EPITHOPES | 2014 |
|
RU2636549C1 |
| EMULSIFIER COMPOSITION AND USE THEREOF | 2019 |
|
RU2793862C2 |
| ANTIBODIES TO PD-1 AND COMPOSITIONS | 2016 |
|
RU2750675C1 |
| NOVEL PEPTIDE WITH 5 LINKED CTL EPITOPES | 2014 |
|
RU2627175C2 |
| NEIL3 PEPTIDES AND VACCINES COMPRISING THEM | 2010 |
|
RU2733985C2 |
| IMMUNITY INDUCER | 2017 |
|
RU2755542C2 |
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| PEPTIDE OBTAINED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER USING IT, IMMUNITY INDUCER AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS | 2016 |
|
RU2714117C2 |
| ANTI-CDH6-ANTIBODY AND ANTI-CDH6-ANTIBODY-DRUG CONJUGATE | 2018 |
|
RU2798285C2 |
